SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting®. We maintain our...

– Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release – – Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction –   ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025. “The Company continues to execute at a high level, including recruitment of 100 patients in our ongoing Halneuron® Phase 2b trial and the addition of a,...

MACAU, Nov. 06, 2025 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the third quarter of 2025. Total operating revenues for the third quarter of 2025 were US$1.31 billion, representing an increase of approximately 11% from US$1.18 billion for the comparable period in 2024. The increase in total operating revenues was primarily attributable to the improved performance in both overall gaming and non-gaming operations. Operating income for the third quarter of 2025 was US$184.5 million, compared with US$138.6 million in the third quarter of 2024. Melco’s Adjusted Property EBITDA(1) was US$380.4 million in the third quarter of 2025, compared...

OMAHA, Neb., Nov. 06, 2025 (GLOBE NEWSWIRE) — On November 6, 2025, Greystone Housing Impact Investors LP (NYSE: GHI) (the “Partnership”) announced financial results for the three months ended September 30, 2025. The Partnership will host a call today at 4:30 p.m. Eastern Time to discuss the results and business outlook. Details for accessing the call can be found below under “Earnings Webcast & Conference Call.” Financial Highlights The Partnership reported the following results as of and for the three months ended September 30, 2025:Net income of $2.0 million or $0.03 per Beneficial Unit Certificate (“BUC”), basic and diluted Cash Available for Distribution (“CAD”) of $4.6 million or $0.20 per BUC Total assets of $1.49 billion Total Mortgage Revenue Bond (“MRB”) and Governmental Issuer Loan (“GIL”) investments...

MACAU, Nov. 06, 2025 (GLOBE NEWSWIRE) — Studio City International Holdings Limited (NYSE: MSC) (“Studio City” or the “Company”), a world-class integrated resort located in Cotai, Macau, today reported its unaudited financial results for the third quarter of 2025. Total operating revenues for the third quarter of 2025 were US$182.5 million, compared with US$174.6 million in the third quarter of 2024. The increase was primarily attributable to better performance in mass market operations leading to an increase in revenue from casino contract. Studio City Casino generated gross gaming revenues of US$344.4 million and US$335.5 million for the third quarters of 2025 and 2024, respectively. Mass market table games drop was US$942.5 million in the third quarter of 2025, compared with US$912.9 million in the third quarter of 2024 and hold...

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Patient recruitment and enrollment in progress for Phase 1/2 STAND study in chronic neuropathic pain following activation of two clinical sites. Expect to dose first patient in the coming months. Held productive interaction with Medicines and Healthcare products Regulatory Agency (MHRA) to...

WILMINGTON, Del., Nov. 06, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup generators, gas pipelines and other critical infrastructure assets, announced results for its three and nine months ended September 30, 2025 (Q3’25 and 9M’25). Acorn will hold an investor call today at 11 a.m. ET (details below).Summary Financial Results ($ in thousands) Q3’25 Q3’24 Change   9M’25 9M’24 ChangeMonitoring revenue $ 1,560   $ 1,138   +37.1 %   $ 4,149   $ 3,350   +23.9 %Hardware revenue $ 918   $ 1,912   -52.0 %   $ 4,952   $ 4,107   +20.6 %Total revenue(1) $ 2,478   $ 3,050   -18.8 %   $ 9,101   $ 7,457   +22.0 %Gross margin   78.5 %   71.7 % +680bps     75.9 %   73.0 % +290bpsNet income to stockholders $ 252   $ 725   -65.2 %   $ 1,436   $ 1,061   +35.3 %Net...

Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial HighlightsTotal net revenue of $67.5 million MACI® net revenue growth of 25% to $55.7 million Burn Care net revenue of $11.8 million, consisting of $10.4 million of Epicel® revenue and $1.5 million of NexoBrid® revenue Gross...

– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated Record Quarterly Pain Portfolio Net Revenue of $167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million – – Ended Q3’25 with Cash, Cash Equivalents and Marketable Securities of $285.9 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter ended September 30, 2025, and provided...

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025; expected to be sufficient to fund operations into Q4 of 2027CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFRm NSCLC,” said Mark Velleca, M.D., Ph.D.,...